Novavax Inc header image

Novavax Inc

NVAX

Equity

ISIN null / Valor 47862952

NASDAQ (2026-04-27)
USD 8.07-1.82%

Novavax Inc
UMushroom community rating:

star star star star star
2.56 5 votes No rating yet
NegativeNeutralPositive

About company

Novavax Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Leveraging proprietary recombinant nanoparticle vaccine technology, Novavax has been at the forefront of developing vaccines for a range of infectious diseases, including its notable efforts in creating a vaccine for COVID-19. The company's approach combines the power of genetic engineering and nanoparticle technology to produce vaccine candidates aimed at eliciting robust immune responses. While the company has gained significant attention for its work during the COVID-19 pandemic, its research and development efforts extend to other infectious diseases as well, positioning Novavax as a key player in the global effort to combat emerging health threats through vaccination.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

21.0%1Y
6.75%3Y
-96.9%5Y

Performance

67.1%1Y
94.6%3Y
102%5Y

Volatility

Market cap

1315 M

Market cap (USD)

Daily traded volume (Shares)

2,656,600

Daily traded volume (Shares)

1 day high/low

8.2 / 7.7

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

2.56

5 votes
Performance:
starstarstarstarstar
3.11
Innovation:
starstarstarstarstar
3.22
Society:
starstarstarstarstar
3.67
Nature:
starstarstarstarstar
2.56
Nicolas Allet
Switzerland, 18 Mar 2026
star star star star star
Novavax faces ongoing financial headwinds as COVID demand fades. The Sanofi partnership offers a lifeline but uncertainty remains high. Protein subunit platform is differentiated yet commercialization beyond COVID is still unproven.
Réka Vass
Switzerland, 28 Mar 2025
star star star star star
Robin Roten
Switzerland, 04 Dec 2022
star star star star star

EQUITIES OF THE SAME SECTOR

Trustpilot Group plc
Trustpilot Group plc Trustpilot Group plc Valor: 110433681
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.47%GBP 2.56
Bread Financial Holdings Inc
Bread Financial Holdings Inc Bread Financial Holdings Inc Valor: 1048752
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.14%USD 88.00
Kudelski SA
Kudelski SA Kudelski SA Valor: 1226836
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.64%CHF 1.24
adesso SE
adesso SE adesso SE Valor: 10467159
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.36%EUR 58.20
Muehlbauer Holding AG
Muehlbauer Holding AG Muehlbauer Holding AG Valor: 916971
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.03%EUR 38.40
Biotest AG
Biotest AG Biotest AG Valor: 327343
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%EUR 41.40
Youngtimers Ltd
Youngtimers Ltd Youngtimers Ltd Valor: 632685
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%CHF 0.45
Elastic N.V.
Elastic N.V. Elastic N.V. Valor: 43878372
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.79%USD 47.45
Joby Aviation Incorporation
Joby Aviation Incorporation Joby Aviation Incorporation Valor: 113133115
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
6.35%USD 9.04
Azenta Inc
Azenta Inc Azenta Inc Valor: 1568240
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.93%USD 25.15